BLFS news

The acquisition adds complementary cell therapy field assets and a high-margin consumables business. Repligen intends to provide financial impact details in its third quarter 2026 earnings call.

Biolife Solutions amended its certificate of incorporation, reducing authorized shares from 100 million to 1 million. This is a corporate administrative update related to the creation of a new capital structure.

BioLife reported a 21% increase in Q2 2026 revenue to $28.5 million. Additionally, the company announced that Repligen will acquire BioLife for approximately $1.5 billion, with the deal expected to close in Q4 2026.

Repligen CEO Olivier Loeillot highlights Bio-Life's industry leadership and outlines the integration of their cell processing operations, targeting a fourth-quarter closing.

Biolife Solutions announced a definitive agreement to acquire Repligen Corp in a cash and stock transaction valued at approximately $3.55 billion. This strategic M&A deal expands Biolife's capabilities in cell and gene therapy manufacturing.

BioLife Solutions released a June 2026 investor presentation outlining its industry-leading solutions for cell-based therapies. The presentation includes financial metrics, non-GAAP measures, and forward-looking statements regarding company operations and market positioning.